
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology Inc's robust growth projections indicate anticipated launch sales of approximately $2.6 billion by 2034, driven by the premium pricing of its lead candidate, cretostimogene grenadenorepvec (Creto), which positions it favorably within the bladder cancer treatment market. The company's focus on addressing an unmet need for effective therapies that reduce disease recurrence, coupled with Creto's differentiated efficacy demonstrated in clinical studies, enhances its potential market adoption among healthcare professionals and patients. Additionally, strategic plans for Creto to expand into different patient populations signal significant revenue opportunities, projected to reach about $1 billion in peak revenues for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Bears say
CG Oncology Inc faces significant risks regarding the commercial viability of its lead therapeutic candidate, cretostimogene grenadenorepvec, due to historical precedents in oncology where products failed in the market despite high pricing and insufficient differentiating advantages. Concerns regarding potential negative trial outcomes, slower-than-expected enrollment, and adverse regulatory decisions pose substantial threats to the timeline and scope of commercial launch, which could ultimately delay revenues. Additionally, vulnerabilities related to intellectual property protection and reimbursement challenges from payers heighten the uncertainty surrounding the company's financial future and market positioning.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares